GO
| HSI1 | 23,753.84 | 0.00 | -- |
| HSCEI1 | 7,981.54 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-16 15:13:12 UBS published a research report saying that the National Healthcare Security Administration announced the 2026 National Reimbursement Drug List and the Commercial Insurance Innovative Drug List. Of the 124 reviewed negotiation or bidding candidate drugs, 107 were included in the reimbursement drug list, while 34 were removed due to factors such as clinical substitution and supply, bringing the total number of drugs covered by the reimbursement list to 3,331, up 2.4% YoY. The negotiation success rate for the national reimbursement drug list remained at a high level. The bank noted that among the 107 newly included drugs, 51 were Class 1 innovative drugs, accounting for nearly half of the total newly added drugs and marking a record high. All 12 negotiated drugs in the Commercial Insurance Innovative Drug List were also included. The bank believes this year's adjustment was broadly stable, with strong industry participation and a high negotiation success rate, although the extent of price cuts will only be confirmed after the two lists officially take effect on Jan 1, 2027. Among pharmaceutical companies, HANSOH PHARMA (03692.HK), CSPC PHARMA (01093.HK), SBP GROUP (01177.HK), SIMCERE PHARMA (02096.HK) and 3SBIO (01530.HK) all had products included or added new indications. (sl/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |